DNLI · ISSUER CIK 1714899
Denali Therapeutics Inc.
Between Aug 1, 2026 and Oct 29, 2026, 4 Denali Therapeutics Inc. insiders reported $0.00 of open-market purchases and $435K of sales on SEC Form 4.
↗4 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 2 of 4 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$435KInsider selling
−$435KNet open-market
Sep 9, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 202616:44 | Sep 4, 2026 | DNLI | Chief Medical Officer | S · SellLate 5d | $22.29 | −1,654 | 204,538 | -1% | −$37K | ||
| Sep 4, 202617:02 | Sep 2, 2026 | DNLI | Director | S · Sell10b5-1 | $22.90 | −11,439 | 19,686 | -37% | −$262K | ||
| Sep 3, 202616:17 | Sep 1, 2026 | DNLI | COFO and Secretary | S · Sell10b5-1 | $23.44 | −2,768 | 278,995 | -1% | −$65K | ||
| Aug 14, 202616:48 | Aug 12, 2026 | DNLI | President and CEO, Director | G · Gift | — | −32,220 | 2,120,384 | -1% | — | ||
| Aug 13, 202617:01 | Aug 11, 2026 | DNLI | COFO and Secretary | S · Sell | $25.07 | −2,857 | 281,763 | -1% | −$72K |